SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA 

Session Chairs: Ching-Hon Pui, MD and Adele Fielding, MD, PhD

Welcome and Opening Remarks | Phillip Scheinberg, MD, PhD | President, Society of Hematologic Oncology

Novel Therapies in T-ALL: From CAR T to Novel Targets | David T. Teachey, MD | The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Optimizing Frontline Therapy: Best Backbone, Less Chemotherapy, and More Immunotherapy | Hagop Kantarjian, MD | MD Anderson Cancer Center, Houston, Texas, USA

CAR T Cells in ALL: Early Integration in Newly Diagnosed High-Risk ALL and Optimization of Post CAR T-Cells Outcome in Relapsed-Refractory Disease | Bijal D. Shah, MD, MS | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Management of Ph-Positive ALL | Yves Chalandon, MD | Geneva University Hospitals HUG, Geneva, Switzerland

MRD in ALL: How to Tailor Therapy? | Aaron C. Logan, MD, PhD, Mphil | University of California, San Francisco, California, USA

Management of Ph-Like ALL: Treatment a la Carte or One Fits All? | Sarah K. Tasian, MD | Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

TP53 Abnormalities in ALL: Impact on Outcome and Optimal Management With Modern Therapies | Nicholas J. Short, MD | MD Anderson Cancer Center, Houston, Texas, USA

Oral Abstract | ALL-712: Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleuce | Elias Jabbour, MD | MD Anderson Cancer Center, Houston, Texas, USA